Assuming the EM AML trial is pending CDX patent submissions.
The reason for the change in tact regarding breast cancer is that preclinical data determined Zantrene makes doxorubicin more effective. Why compete with an established market when you can improve it?
General Comments / Chat, page-4808
-
-
- There are more pages in this discussion • 7,094 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.53 |
Change
-0.060(3.77%) |
Mkt cap ! $260.7M |
Open | High | Low | Value | Volume |
$1.59 | $1.59 | $1.53 | $83.43K | 53.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20575 | $1.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.57 | 300 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20575 | 1.530 |
1 | 500 | 1.525 |
1 | 2750 | 1.510 |
4 | 14647 | 1.505 |
7 | 18242 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.570 | 300 | 1 |
1.590 | 10776 | 3 |
1.600 | 23400 | 1 |
1.650 | 17029 | 2 |
1.690 | 6570 | 3 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online